Limits...
Comparative Metabolomic Analysis of the Neuroprotective Effects of Scutellarin and Scutellarein against Ischemic Insult.

Tang H, Tang Y, Li NG, Lin H, Li W, Shi Q, Zhang W, Zhang P, Dong Z, Shen M, Gu T, Duan JA - PLoS ONE (2015)

Bottom Line: Scutellarein (Scue), the major Scu metabolite in vivo, exhibits heightened neuroprotective effects when compared to Scu.We found that metabolic changes after ischemic injury returned to near-normal levels after Scue intervention, unlike Scu treatment, further validating the heightened protective effects exerted by Scue compared to Scu.These results demonstrate that Scue is a potential drug for treatment of ischemic insult.

View Article: PubMed Central - PubMed

Affiliation: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.

ABSTRACT
For more than thirty years, scutellarin (Scu) has been used in China to clinically treat acute cerebral infarction and paralysis. Scutellarein (Scue), the major Scu metabolite in vivo, exhibits heightened neuroprotective effects when compared to Scu. To explore the neuroprotective role of these compounds, we performed ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UHPLC-QTOF/MS) coupled with a pattern recognition approach to investigate metabolomic differences in a rat model of ischemia after treatment with each compound. We examined metabolites in urine, hippocampal tissue, and plasma, and we tentatively identified 23 endogenous metabolites whose levels differed significantly between sham-operated and model groups. Upon pathway analysis, we found an additional 11 metabolic pathways in urine, 14 metabolic pathways in the hippocampal tissue, and 3 metabolic pathways in plasma. These endogenous metabolites were mainly involved in sphingolipid metabolism, lysine biosynthesis, and alanine, aspartate, and glutamate metabolism. We found that metabolic changes after ischemic injury returned to near-normal levels after Scue intervention, unlike Scu treatment, further validating the heightened protective effects exerted by Scue compared to Scu. These results demonstrate that Scue is a potential drug for treatment of ischemic insult.

No MeSH data available.


Related in: MedlinePlus

Plasma PCA score plot (A), S-plot of OPLS-DA data (B), hippocampal tissue PCA score plot (C), and S-plot of OPLS-DA data between the sham-operated and model groups in negative mode (D).C, sham-operated group, M, model group.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493097&req=5

pone.0131569.g002: Plasma PCA score plot (A), S-plot of OPLS-DA data (B), hippocampal tissue PCA score plot (C), and S-plot of OPLS-DA data between the sham-operated and model groups in negative mode (D).C, sham-operated group, M, model group.

Mentions: The plasma samples from the sham-operated and model groups were separated into two clusters in the PCA analysis, indicating that their metabolic profiles had changed as a result of ischemia and reperfusion (Fig 2A and 2B). The PCA score plots provided an overview of the metabolic composition of a group, however, detailed differences between samples in each cluster remained unclear. Significant differences between endogenous metabolites in the sham-operated and model groups were determined from an S-plot of the OPLS-DA. According to the PCA score plot analysis for hippocampal tissue samples, the sham-operated and model groups were separated into two clusters, suggesting that they had different metabolic profiles. The S-plots of OPLS-DA were obtained by MarkerLynx analysis (Fig 2C and 2D).


Comparative Metabolomic Analysis of the Neuroprotective Effects of Scutellarin and Scutellarein against Ischemic Insult.

Tang H, Tang Y, Li NG, Lin H, Li W, Shi Q, Zhang W, Zhang P, Dong Z, Shen M, Gu T, Duan JA - PLoS ONE (2015)

Plasma PCA score plot (A), S-plot of OPLS-DA data (B), hippocampal tissue PCA score plot (C), and S-plot of OPLS-DA data between the sham-operated and model groups in negative mode (D).C, sham-operated group, M, model group.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493097&req=5

pone.0131569.g002: Plasma PCA score plot (A), S-plot of OPLS-DA data (B), hippocampal tissue PCA score plot (C), and S-plot of OPLS-DA data between the sham-operated and model groups in negative mode (D).C, sham-operated group, M, model group.
Mentions: The plasma samples from the sham-operated and model groups were separated into two clusters in the PCA analysis, indicating that their metabolic profiles had changed as a result of ischemia and reperfusion (Fig 2A and 2B). The PCA score plots provided an overview of the metabolic composition of a group, however, detailed differences between samples in each cluster remained unclear. Significant differences between endogenous metabolites in the sham-operated and model groups were determined from an S-plot of the OPLS-DA. According to the PCA score plot analysis for hippocampal tissue samples, the sham-operated and model groups were separated into two clusters, suggesting that they had different metabolic profiles. The S-plots of OPLS-DA were obtained by MarkerLynx analysis (Fig 2C and 2D).

Bottom Line: Scutellarein (Scue), the major Scu metabolite in vivo, exhibits heightened neuroprotective effects when compared to Scu.We found that metabolic changes after ischemic injury returned to near-normal levels after Scue intervention, unlike Scu treatment, further validating the heightened protective effects exerted by Scue compared to Scu.These results demonstrate that Scue is a potential drug for treatment of ischemic insult.

View Article: PubMed Central - PubMed

Affiliation: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.

ABSTRACT
For more than thirty years, scutellarin (Scu) has been used in China to clinically treat acute cerebral infarction and paralysis. Scutellarein (Scue), the major Scu metabolite in vivo, exhibits heightened neuroprotective effects when compared to Scu. To explore the neuroprotective role of these compounds, we performed ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UHPLC-QTOF/MS) coupled with a pattern recognition approach to investigate metabolomic differences in a rat model of ischemia after treatment with each compound. We examined metabolites in urine, hippocampal tissue, and plasma, and we tentatively identified 23 endogenous metabolites whose levels differed significantly between sham-operated and model groups. Upon pathway analysis, we found an additional 11 metabolic pathways in urine, 14 metabolic pathways in the hippocampal tissue, and 3 metabolic pathways in plasma. These endogenous metabolites were mainly involved in sphingolipid metabolism, lysine biosynthesis, and alanine, aspartate, and glutamate metabolism. We found that metabolic changes after ischemic injury returned to near-normal levels after Scue intervention, unlike Scu treatment, further validating the heightened protective effects exerted by Scue compared to Scu. These results demonstrate that Scue is a potential drug for treatment of ischemic insult.

No MeSH data available.


Related in: MedlinePlus